AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15623713 — intervention group
Group type: COMPARATOR
Intervention: High-frequency (5 Hz) repetitive transcranial magnetic stimulation (rTMS) applied over the supplementary motor area
Number of subjects: 0
Study 10907353 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone 5 to 7.5 mg per day
Number of subjects: 36
Study 10907353 — intervention group
Group type: COMPARATOR
Intervention: Non-steroid control group
Number of subjects: 36
Study 9049578 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol 5 mg once daily for 7 days
Number of subjects: 12
Study 9049578 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol 5 mg once daily for 1 day
Number of subjects: 12
Study 9049578 — intervention group
Group type: COMPARATOR
Intervention: Atenolol 25 mg once daily for 7 days
Number of subjects: 12
Study 9049578 — intervention group
Group type: COMPARATOR
Intervention: Atenolol 100 mg once daily for 7 days
Number of subjects: 12
Study 8244259 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 MU recombinant interferon-alpha 2b
Number of subjects: 59
Study 8244259 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 MU recombinant interferon-alpha 2b
Number of subjects: 59
Study 8244259 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 3748634 — intervention group
Group type: EXPERIMENTAL
Intervention: Tonic stimuli (5-minute projected white triangle or circle) with phasic stimuli (5-second red or green square) paired with shock.
Number of subjects: 48
Study 3748634 — intervention group
Group type: COMPARATOR
Intervention: Tonic stimuli (5-minute projected white triangle or circle) with phasic stimuli (5-second red or green square) alone.
Number of subjects: 48
Study 3748634 — intervention group
Group type: EXPERIMENTAL
Intervention: Phasic stimuli controlled by different phasic stimuli.
Number of subjects: 48
Study 29509641 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg·kg caffeine
Number of subjects: 101
Study 29509641 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg·kg caffeine
Number of subjects: 101
Study 29509641 — intervention group
Group type: COMPARATOR
Intervention: 0 mg·kg caffeine (placebo)
Number of subjects: 101
Study 27448485 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotigotine
Number of subjects: 42
Study 27448485 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 24828838 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive restructuring skill acquisition during group CBT
Number of subjects: 44
Study 24828838 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardised CBT
Number of subjects: 44
Study 20593332 — intervention group
Group type: EXPERIMENTAL
Intervention: Water immersion
Number of subjects: 229
Study 20593332 — intervention group
Group type: COMPARATOR
Intervention: Standard air insufflation
Number of subjects: 229
Study 18410471 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin (20 to 320 mg/day)
Number of subjects: 31
Study 18410471 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin (80 mg/day or less)
Number of subjects: 31
Study 18410471 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin
Number of subjects: 31
Study 15729576 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin detemir
Number of subjects: 7
Study 15729576 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose insulin detemir
Number of subjects: 7
Study 15729576 — intervention group
Group type: COMPARATOR
Intervention: NPH insulin
Number of subjects: 7
Study 11839710 — intervention group
Group type: EXPERIMENTAL
Intervention: Oats diet (allowed to eat oats freely in conjunction with a gluten free diet)
Number of subjects: 92
Study 11839710 — intervention group
Group type: COMPARATOR
Intervention: Conventional gluten free diet (control group)
Number of subjects: 92
Study 10379115 — intervention group
Group type: EXPERIMENTAL
Intervention: Demineralized freeze‐dried bone allograft (DFDBA) with expanded polytetrafluoroethylene (e‐PTFE) membrane
Number of subjects: 8
Study 10379115 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated sites)
Number of subjects: 8
Study 10379115 — intervention group
Group type: EXPERIMENTAL
Intervention: Demineralized freeze‐dried bone allograft (DFDBA)
Number of subjects: 8
Study 8818852 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin 500 mg/day orally once daily for 3 days
Number of subjects: 204
Study 8818852 — intervention group
Group type: COMPARATOR
Intervention: Roxithromycin 150 mg orally twice daily for 10 days
Number of subjects: 204
Study 1882897 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate (Sc) 6 g/day
Number of subjects: 125
Study 1882897 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine (Rn) 150 mg
Number of subjects: 125
Study 7078714 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose diazepam (150-200 mg/day)
Number of subjects: 0
Study 7078714 — intervention group
Group type: COMPARATOR
Intervention: High dose diazepam (150-200 mg/day) with naloxone (30 mg i.v.)
Number of subjects: 0
Study 31865423 — intervention group
Group type: EXPERIMENTAL
Intervention: Caloric restriction with fish oil (CRF)
Number of subjects: 21
Study 31865423 — intervention group
Group type: COMPARATOR
Intervention: Caloric restriction (CR)
Number of subjects: 21
Study 30998048 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive Affect Treatment (PAT)
Number of subjects: 96
Study 30998048 — intervention group
Group type: COMPARATOR
Intervention: Negative Affect Treatment (NAT)
Number of subjects: 96
Study 28497325 — intervention group
Group type: EXPERIMENTAL
Intervention: PCIRV (Pressure-Controlled Inverse Ratio Ventilation) with I:E ratio of 1.5:1
Number of subjects: 60
Study 28497325 — intervention group
Group type: EXPERIMENTAL
Intervention: PCIRV (Pressure-Controlled Inverse Ratio Ventilation)
Number of subjects: 60
Study 28497325 — intervention group
Group type: COMPARATOR
Intervention: VCV (Volume-Control Ventilation) with I:E ratio of 1:2
Number of subjects: 60
Study 26124033 — intervention group
Group type: EXPERIMENTAL
Intervention: Tooth-borne hyrax appliance
Number of subjects: 25
Study 26124033 — intervention group
Group type: COMPARATOR
Intervention: Tooth-bone-borne hybrid hyrax appliance
Number of subjects: 25
Study 26124033 — intervention group
Group type: EXPERIMENTAL
Intervention: Both appliances
Number of subjects: 25
Study 23963965 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion hydrochloride extended-release (XL) for 8 weeks
Number of subjects: 51
Study 22073981 — intervention group
Group type: EXPERIMENTAL
Intervention: Classroom-based crew resource management (CRM) training, 2-day duration
Number of subjects: 6
Study 22073981 — intervention group
Group type: COMPARATOR
Intervention: Matched control ICUs (no CRM training)
Number of subjects: 6
Study 18795965 — intervention group
Group type: EXPERIMENTAL
Intervention: HAART
Number of subjects: 178
Study 16403108 — intervention group
Group type: EXPERIMENTAL
Intervention: Emla (lignocaine 2.5% and prilocaine 2.5%)
Number of subjects: 14
Study 16403108 — intervention group
Group type: COMPARATOR
Intervention: Aqueous cream (placebo)
Number of subjects: 14
Study 16403108 — intervention group
Group type: EXPERIMENTAL
Intervention: Emla
Number of subjects: 14
Study 12793914 — intervention group
Group type: EXPERIMENTAL
Intervention: Heliox (helium/oxygen, 80:20)
Number of subjects: 20
Study 12793914 — intervention group
Group type: COMPARATOR
Intervention: Oxygen
Number of subjects: 20
Study 10449279 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily didanosine (ddI) plus twice-daily stavudine (d4T)
Number of subjects: 87
Study 10449279 — intervention group
Group type: COMPARATOR
Intervention: Twice-daily didanosine (ddI) plus twice-daily stavudine (d4T)
Number of subjects: 87
Study 10449279 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 87
Study 7605759 — intervention group
Group type: EXPERIMENTAL
Intervention: Alkalinized mepivacaine (1 mL sodium bicarbonate per 10 mL mepivacaine)
Number of subjects: 40
Study 7605759 — intervention group
Group type: COMPARATOR
Intervention: Saline control (equal volume of saline added to mepivacaine)
Number of subjects: 40
Study 2260046 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting propranolol (LA.P) 160 mg once-daily
Number of subjects: 55
Study 2260046 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 682655 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed mitral commissurotomy
Number of subjects: 39
Study 682655 — intervention group
Group type: COMPARATOR
Intervention: Open mitral commissurotomy
Number of subjects: 39
Study 7138725 — intervention group
Group type: EXPERIMENTAL
Intervention: Air and 3-4% ether
Number of subjects: 60
Study 7138725 — intervention group
Group type: EXPERIMENTAL
Intervention: Air and 0.5% trichloroethylene
Number of subjects: 60
Study 7138725 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide
Number of subjects: 60
Study 7138725 — intervention group
Group type: COMPARATOR
Intervention: Oxygen and intermittent i.v. morphine or pethidine
Number of subjects: 60
Study 30882149 — intervention group
Group type: EXPERIMENTAL
Intervention: SNP-based model under control conditions
Number of subjects: 267
Study 30882149 — intervention group
Group type: EXPERIMENTAL
Intervention: SNP-based model under water deficit conditions
Number of subjects: 267
Study 30882149 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical genomic prediction (GP) model under control conditions
Number of subjects: 267
Study 30882149 — intervention group
Group type: COMPARATOR
Intervention: Control conditions
Number of subjects: 267
Study 30882149 — intervention group
Group type: EXPERIMENTAL
Intervention: Water deficit conditions
Number of subjects: 267
Study 30099583 — intervention group
Group type: EXPERIMENTAL
Intervention: Training by Vietnamese salon owners
Number of subjects: 200
Study 26872295 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (EX; 60 min at 60% maximal oxygen uptake)
Number of subjects: 12
Study 26872295 — intervention group
Group type: COMPARATOR
Intervention: Control (CON; without exercise)
Number of subjects: 12
Study 26872295 — intervention group
Group type: EXPERIMENTAL
Intervention: Both EX and CON
Number of subjects: 12
Study 24451690 — intervention group
Group type: EXPERIMENTAL
Intervention: Horizontal hip joint angle (H-HJA) test
Number of subjects: 138
Study 24451690 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertical hip joint angle (V-HJA) test
Number of subjects: 138
Study 24451690 — intervention group
Group type: COMPARATOR
Intervention: Passive straight-leg raise (PSLR) test
Number of subjects: 138
Study 22503020 — intervention group
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA 200 U
Number of subjects: 416
Study 22503020 — intervention group
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA 300 U
Number of subjects: 416
Study 22503020 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 416
Study 20122366 — intervention group
Group type: EXPERIMENTAL
Intervention: quetiapine 300 mg/d
Number of subjects: 740
Study 20122366 — intervention group
Group type: EXPERIMENTAL
Intervention: quetiapine 600 mg/d
Number of subjects: 740
Study 20122366 — intervention group
Group type: EXPERIMENTAL
Intervention: paroxetine 20 mg/d
Number of subjects: 740
Study 20122366 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 740
Study 17327187 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine gluconate-impregnated cloth (PC)
Number of subjects: 30
Study 17327187 — intervention group
Group type: COMPARATOR
Intervention: 4% chlorhexidine gluconate surgical skin preparation (SP)
Number of subjects: 30
Study 17327187 — intervention group
Group type: COMPARATOR
Intervention: Comparison of PC and SP
Number of subjects: 30
Study 15606444 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac-K 12.5 mg orally
Number of subjects: 10
Study 15606444 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac-K 25 mg orally
Number of subjects: 10
Study 15606444 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac-K 22.5 mg via short-term i.v. infusion
Number of subjects: 10
Study 15606444 — intervention group
Group type: COMPARATOR
Intervention: Comparison of 12.5 mg and 25 mg oral doses
Number of subjects: 10
Study 11865964 — intervention group
Group type: EXPERIMENTAL
Intervention: 125 mg bosentan tablet (with food)
Number of subjects: 16
Study 11865964 — intervention group
Group type: EXPERIMENTAL
Intervention: 125 mg bosentan tablet (without food)
Number of subjects: 16
Study 11865964 — intervention group
Group type: EXPERIMENTAL
Intervention: Two tablets of 62.5 mg bosentan (with food)
Number of subjects: 16
Study 11865964 — intervention group
Group type: COMPARATOR
Intervention: Suspension of bosentan (without food)
Number of subjects: 16
Study 10416558 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise program (12 weeks)
Number of subjects: 28
Study 10416558 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 28
Study 7555159 — intervention group
Group type: EXPERIMENTAL
Intervention: Anistreplase (30 U/5 min) + heparin
Number of subjects: 159
Study 7555159 — intervention group
Group type: COMPARATOR
Intervention: Heparin-only therapy
Number of subjects: 159
Study 7555159 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistently occluded vessel or increased coronary artery stenosis
Number of subjects: 159
Study 7555159 — intervention group
Group type: EXPERIMENTAL
Intervention: Reopened vessel or reduced coronary artery stenosis
Number of subjects: 159
Study 7555159 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 159
Study 2207562 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior lesser curve seromyotomy with posterior truncal vagotomy (AMPT, n = 77)
Number of subjects: 146
Study 2207562 — intervention group
Group type: COMPARATOR
Intervention: Truncal vagotomy and pyloroplasty (TVP, n = 69)
Number of subjects: 146
Study 2207562 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior lesser curve seromyotomy with posterior truncal vagotomy (AMPT)
Number of subjects: 146
Study 2207562 — intervention group
Group type: COMPARATOR
Intervention: Truncal vagotomy and pyloroplasty (TVP)
Number of subjects: 146
Study 2207562 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall Visick grading
Number of subjects: 146
Study 7386801 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium salicylate administration in large amounts
Number of subjects: 0
Study 7386801 — intervention group
Group type: COMPARATOR
Intervention: Diet devoid of salicylate-containing food
Number of subjects: 0
Study 31358387 — intervention group
Group type: EXPERIMENTAL
Intervention: Lutein and zeaxanthin
Number of subjects: 4203
Study 31358387 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids
Number of subjects: 4203
Study 31358387 — intervention group
Group type: EXPERIMENTAL
Intervention: Both lutein and zeaxanthin and omega-3 fatty acids
Number of subjects: 4203
Study 31358387 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4203
Study 31358387 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified AREDS supplements (lower zinc dosage, omission of β-carotene, both, or no modification)
Number of subjects: 4203
Study 27568392 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote monitoring (Remote arm)
Number of subjects: 865
Study 27568392 — intervention group
Group type: COMPARATOR
Intervention: Standard monitoring (Standard arm)
Number of subjects: 865
Study 27231940 — intervention group
Group type: EXPERIMENTAL
Intervention: Onabotulintoxin A (BontA)
Number of subjects: 20
Study 27231940 — intervention group
Group type: COMPARATOR
Intervention: Saline solution injection (Control)
Number of subjects: 20
Study 24405257 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise with mechanical traction
Number of subjects: 86
Study 24405257 — intervention group
Group type: COMPARATOR
Intervention: Exercise
Number of subjects: 86
Study 24405257 — intervention group
Group type: COMPARATOR
Intervention: Exercise with over-door traction
Number of subjects: 86
Study 21519221 — intervention group
Group type: EXPERIMENTAL
Intervention: New dose regimen of artesunate and amodiaquine (NDRAA)
Number of subjects: 304
Study 21519221 — intervention group
Group type: COMPARATOR
Intervention: Standard dose regimen of artesunate and amodiaquine (SDRAA)
Number of subjects: 304
Study 21519221 — intervention group
Group type: COMPARATOR
Intervention: Fixed-dose artesunate-amodiaquine (FDAA)
Number of subjects: 304
Study 21519221 — intervention group
Group type: COMPARATOR
Intervention: Artemether-lumefantrine (AL)
Number of subjects: 304
Study 19650425 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound therapy (0.05-1.5 W/cm2, 1 MHz frequency, 3-9 minutes per session, 10 sessions total)
Number of subjects: 29
Study 19650425 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound therapy (0.5-1.5 W/cm2, 4-9 minutes per session)
Number of subjects: 29
Study 19650425 — intervention group
Group type: COMPARATOR
Intervention: Control group (10 patients without ultrasound influence)
Number of subjects: 29
Study 17455439 — intervention group
Group type: EXPERIMENTAL
Intervention: Glass fiber‐reinforced post (FRP)
Number of subjects: 100
Study 17455439 — intervention group
Group type: COMPARATOR
Intervention: Metal screw posts (MSP)
Number of subjects: 100
Study 15111679 — intervention group
Group type: EXPERIMENTAL
Intervention: Pergolide 0.25 to 0.75 mg in the evening for 6 weeks
Number of subjects: 100
Study 15111679 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label pergolide up to 1.5 mg/d for 12 months
Number of subjects: 100
Study 15111679 — intervention group
Group type: COMPARATOR
Intervention: Open-label pergolide after switching from placebo
Number of subjects: 100
Study 11868930 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 100 microg and salmeterol 50 microg combination product (FSC) twice daily
Number of subjects: 432
Study 9814494 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol monotherapy after 7 days
Number of subjects: 42
Study 9814494 — intervention group
Group type: COMPARATOR
Intervention: Hyperthyroid state
Number of subjects: 42
Study 7897129 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (n = 16)
Number of subjects: 26
Study 7897129 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (n = 10)
Number of subjects: 26
Study 2694229 — intervention group
Group type: EXPERIMENTAL
Intervention: Piracetam
Number of subjects: 0
Study 2694229 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxiracetam
Number of subjects: 0
Study 2694229 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 324620 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide given continuously with methotrexate, 5‐fluorouracil, vincristine, and prednisone given intermittently
Number of subjects: 51
Study 324620 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide given continuously
Number of subjects: 51
Study 31470754 — intervention group
Group type: EXPERIMENTAL
Intervention: Matched intervention group (preferred intervention)
Number of subjects: 172
Study 31470754 — intervention group
Group type: COMPARATOR
Intervention: Mismatched intervention group (non-preferred intervention)
Number of subjects: 172
Study 31411373 — intervention group
Group type: EXPERIMENTAL
Intervention: Turmeric-based beverage (TUR) before medium-fat (MF) breakfast
Number of subjects: 12
Study 31411373 — intervention group
Group type: EXPERIMENTAL
Intervention: Turmeric-based beverage (TUR) before high-fat (HF) breakfast
Number of subjects: 12
Study 31411373 — intervention group
Group type: COMPARATOR
Intervention: Flavored water without turmeric before medium-fat (MF) breakfast
Number of subjects: 12
Study 31411373 — intervention group
Group type: COMPARATOR
Intervention: Flavored water without turmeric before high-fat (HF) breakfast
Number of subjects: 12
Study 27785736 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric-coated aspirin administered before a meal (30 min before a meal)
Number of subjects: 572
Study 27785736 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric-coated aspirin administered before sleep
Number of subjects: 572
Study 27785736 — intervention group
Group type: COMPARATOR
Intervention: Enteric-coated aspirin administered during a meal
Number of subjects: 572
Study 27785736 — intervention group
Group type: COMPARATOR
Intervention: Enteric-coated aspirin administered after a meal (30 min after a meal)
Number of subjects: 572
Study 27785736 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric-coated aspirin administered before a meal or before sleep
Number of subjects: 572
Study 27785736 — intervention group
Group type: COMPARATOR
Intervention: Enteric-coated aspirin administered after a meal
Number of subjects: 572
Study 25423326 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy dietary supplement (90 mg of isoflavone)
Number of subjects: 60
Study 25423326 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose hormone therapy (1 mg of estradiol plus 0.5 mg of norethisterone)
Number of subjects: 60
Study 25423326 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 23315161 — intervention group
Group type: EXPERIMENTAL
Intervention: Anagrelide
Number of subjects: 259
Study 23315161 — intervention group
Group type: COMPARATOR
Intervention: Hydroxyurea
Number of subjects: 259
Study 21712835 — intervention group
Group type: EXPERIMENTAL
Intervention: Inulin (24 g)
Number of subjects: 18
Study 21712835 — intervention group
Group type: COMPARATOR
Intervention: Glucose (75 g)
Number of subjects: 18
Study 18494727 — intervention group
Group type: EXPERIMENTAL
Intervention: Scleral buckling without retinopexy (group 1)
Number of subjects: 55
Study 18494727 — intervention group
Group type: COMPARATOR
Intervention: Scleral buckling with retinal cryopexy (group 2)
Number of subjects: 55
Study 17176177 — intervention group
Group type: EXPERIMENTAL
Intervention: Trauma-focused imaginal exposure
Number of subjects: 43
Study 17176177 — intervention group
Group type: COMPARATOR
Intervention: Imagery-based relaxation
Number of subjects: 43
Study 14521739 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulinastatin 12,000 unit/kg (half given intravenously 10 min before aorta cannulation and half added into the priming fluid)
Number of subjects: 20
Study 14521739 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (same volume as ulinastatin)
Number of subjects: 20
Study 11132019 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodialysis (HD)
Number of subjects: 60
Study 11132019 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Ambulatory Peritoneal Dialysis (CAPD)
Number of subjects: 60
Study 11132019 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal subjects)
Number of subjects: 60
Study 8848324 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 cm H2O of CPAP
Number of subjects: 10